Explain this page
Arphra AIPlain-English read on Incyte Corporation’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$388.87
+260.38% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
8bull5bear
±5% threshold
Analyst PT consensus: $109.50 (+1.48%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.37% | +6.96% | +9.18% | +17.60% | +13.44% | +9.58% | +56.36% | +74.28% | +30.97% | +35.27% | +5672.27% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$14.23M
10 txns
Net flow
−$14.23M
Aftermarket
LiveLast trade
$107.91
116 sh
Bid
$107.24
300 sh
Ask
$108.56
257 sh
Spread
$1.320
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $1.27B | $303.33M | $1.47 |
| Q4 Dec 2025 | $1.51B | $299.28M | $1.46 |
| Q3 Sep 2025 | $1.37B | $424.17M | $2.11 |
| Q2 Jun 2025 | $1.22B | $405M | $2.04 |
| Q1 Mar 2025 | $1.05B | $158.2M | $0.80 |
| Q4 Dec 2024 | $1.18B | $201.21M | $1.02 |
Sector & industry today
LiveSectors
- Basic Materials+2.94%
- Industrials+2.57%
- Technology+2.09%
- Consumer Cyclical+1.53%
- Utilities+1.19%
- Healthcare+0.85%
- Financial Services+0.48%
- Communication Services-0.41%
- Real Estate-0.49%
- Consumer Defensive-0.59%
- Energy-2.78%
Top industries (issuer's industry highlighted)
- Biotechnology+2.27%
- Travel Services+7.28%
- Copper+6.43%
- Silver+6.40%
- Leisure+6.11%
- Solar+6.09%
- Other Precious Metals+5.40%
- Manufacturing - Metal Fabrication+5.39%
- Electronic Gaming & Multimedia+5.39%
- Airlines, Airports & Air Services+5.14%
- Computer Hardware+5.11%
- Department Stores+5.04%
Analyst view
DB · price_targets + analyst_gradesConsensus target
$109.50
+1.48% upside
Low
$90.00
Median
$108.50
High
$135.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offeringsinvestors.com·Jun 11, 2026
- Here's Why Incyte (INCY) is a Strong Value Stockzacks.com·Jun 11, 2026
- Incyte: I Am Moving From Hold To Buyseekingalpha.com·Jun 10, 2026
- Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2Bzacks.com·Jun 09, 2026
- Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potentialbenzinga.com·Jun 09, 2026
- Incyte Corporation (INCY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 09, 2026
- Incyte Corporation (INCY) M&A Call Transcriptseekingalpha.com·Jun 08, 2026
- Here's Why Incyte (INCY) is a Strong Growth Stockzacks.com·Jun 08, 2026
Recent analyst activity
DB- Jun 10, 2026PT$140.00Incyte (INCY) PT Raised to $140 at H.C. WainwrightH.C. Wainwright
- Jun 10, 2026GradeBuy → BuyIncyte (INCY) PT Raised to $140 at H.C. WainwrightH.C. Wainwright
- Jun 09, 2026PT$123.00Stifel Reiterates Buy Rating on Incyte (INCY)Stifel Nicolaus
- Jun 09, 2026GradeHold → HoldStifel Reiterates Buy Rating on Incyte (INCY)Cowen & Co.
- Jun 08, 2026PT$107.00Incyte price target raised to $107 from $90 at OppenheimerOppenheimer
- Jun 08, 2026GradePerform → PerformIncyte price target raised to $107 from $90 at OppenheimerOppenheimer
- Jun 08, 2026GradeOutperform → OutperformIncyte (INCY) PT Raised to $107 at OppenheimerOppenheimer
- Jun 02, 2026GradeMarket Perform → Market PerformIncyte (INCY) Reiterated at Market Perform by Citizens Amid Positive Trial ResultsCitigroup
Peers
- BIIBBiogen Inc.$187.06$27.62B
- UTHRUnited Therapeutics Corporation$570.40$25B
- DGXQuest Diagnostics Incorporated$192.67$21.33B
- WSTWest Pharmaceutical Services, Inc.$300.68$21.24B
- RPRXRoyalty Pharma plc$49.47$21.19B
- ILMNIllumina, Inc.$135.78$20.63B
- WATWaters Corporation$307.12$18.28B
- GMABGenmab A/S$26.45$16.3B
Total assets
$6.96B
Total debt
$69.43M
Cash & equiv
$3.1B
Operating CF
$1.41B
Free cash flow
$1.35B
Buybacks
-$19.1M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
CAGNONI PABLO J officer: President, Global Head of R&D | Sell | 18,667 | $1.8M | Apr 17, 2026 |
CAGNONI PABLO J officer: President, R&D | Sell | 18,667 | $1.76M | Mar 17, 2026 |
CAGNONI PABLO J officer: President, R&D | Sell | 18,668 | $1.88M | Feb 19, 2026 |
Issa Mohamed Khairie officer: EVP, Head of US Oncology | Sell | 10,856 | $1.18M | Jan 07, 2026 |
Stein Steven H officer: EVP & Chief Medical Officer | Sell | 15,634 | $1.59M | Jan 05, 2026 |
Tray Thomas officer: Principal Accounting Officer | Sell | 2,774 | $277.4K | Dec 19, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $5.14B | $1.34B | $1.29B | $6.41 | +25.03% |
| FY 2024 | $4.24B | $80.14M | $32.62M | $0.15 | +0.77% |
| FY 2023 | $3.7B | $651.77M | $597.6M | $2.65 | +16.17% |
| FY 2022 | $3.39B | $599.56M | $340.66M | $1.52 | +10.04% |
| FY 2021 | $2.99B | $637.54M | $948.58M | $4.27 | +31.76% |